Q5139 HCPCS Level II code: Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
CMS terminated Q5139: its last date of service was Mar 31, 2025. It stays here for looking up older claims; newer services need a current code.
Official description
Q5139Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
Short description: Inj, eculizumab-aeeb, 10 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with Q5139 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2025
- Terminated after
- Mar 31, 2025
Where Q5139 sits
- 1Q codesTemporary codes
- 2Terminated Q5139Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q5139 still valid?
No. CMS terminated Q5139; its last date of service was Mar 31, 2025. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q5139?
CMS lists Q5139’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q5139
All Q codesQ5133Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mgQ5134Injection, natalizumab-sztn (tyruko), biosimilar, 1 mgQ5135Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mgQ5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mgQ5137Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mgQ5138Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mgQ5140Injection, adalimumab-fkjp, biosimilar, 1 mgQ5141Injection, adalimumab-aaty, biosimilar, 1 mgQ5142Injection, adalimumab-ryvk biosimilar, 1 mgQ5143Injection, adalimumab-adbm, biosimilar, 1 mgQ5144Injection, adalimumab-aacf (idacio), biosimilar, 1 mgQ5145Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg